neoplasm antibodies

Summary

Summary: Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.

Top Publications

  1. doi Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
    Alasdair J Coles
    N Engl J Med 359:1786-801. 2008
  2. ncbi Update on monoclonal antibody therapy in chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Adv Hematol Oncol 2:107-13. 2004
  3. ncbi Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology Surgery, University of California at Los Angeles, CA, USA
    J Clin Oncol 23:8968-77. 2005
  4. ncbi Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation
    Anantharaman Vathsala
    Department of Renal Medicine, Singapore General Hospital, Singapore
    Transplantation 80:765-74. 2005
  5. ncbi Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression
    S M Flechner
    Transplant Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Transplant 5:3009-14. 2005
  6. ncbi High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
    Blood 99:4357-63. 2002
  7. ncbi Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future
    Duxin Sun
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Surg Oncol 96:297-308. 2007
  8. ncbi Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer
    G E Trivers
    Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 2:1767-75. 1996
  9. pmc Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study
    A A McCormick
    Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688, USA
    Proc Natl Acad Sci U S A 105:10131-6. 2008
  10. ncbi Generating improved single-chain Fv molecules for tumor targeting
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol Methods 231:249-60. 1999

Detail Information

Publications219 found, 100 shown here

  1. doi Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
    Alasdair J Coles
    N Engl J Med 359:1786-801. 2008
    ..Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis...
  2. ncbi Update on monoclonal antibody therapy in chronic lymphocytic leukemia
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Adv Hematol Oncol 2:107-13. 2004
    ..This review provides historical context and detailed analysis of current developments, as well as an outline for future prospects and expectations in this exciting new arena of therapeutics...
  3. ncbi Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology Surgery, University of California at Los Angeles, CA, USA
    J Clin Oncol 23:8968-77. 2005
    ..A phase I trial was conducted to test the safety of CP-675,206...
  4. ncbi Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation
    Anantharaman Vathsala
    Department of Renal Medicine, Singapore General Hospital, Singapore
    Transplantation 80:765-74. 2005
    ..A randomized, multicenter, controlled trial was undertaken to evaluate the safety and efficacy of Alemtuzumab, a powerful lytic agent for both T and B lymphocytes, in the prophylaxis of rejection in renal transplantation (RTx)...
  5. ncbi Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression
    S M Flechner
    Transplant Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Transplant 5:3009-14. 2005
    ..The reported higher than expected rate of acute rejection, leukopenia and possible pulmonary toxicity suggests excessive morbidity. Modifications such as an initial period of CNI use should be considered...
  6. ncbi High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
    Suparno Chakrabarti
    Department of Haematology, Birmingham Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom
    Blood 99:4357-63. 2002
    ..The use of Campath-1H appeared to be associated with a low incidence of GVHD but a high incidence of CMV infections and prolonged immune paresis...
  7. ncbi Radioimmunoguided surgery (RIGS), PET/CT image-guided surgery, and fluorescence image-guided surgery: past, present, and future
    Duxin Sun
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Surg Oncol 96:297-308. 2007
    ..PET/CT image-guided surgery only detects later stage disease. Fluorescence image-guided surgery using anti-TAG-72 antibodies may provide opportunities for intraoperative cancer detection of both gross and occult tumors...
  8. ncbi Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer
    G E Trivers
    Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 2:1767-75. 1996
    ..These results indicate that p53-Abs may facilitate the early diagnosis of cancer in a subset of smokers with chronic obstructive pulmonary disease who are at an increased cancer risk...
  9. pmc Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study
    A A McCormick
    Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688, USA
    Proc Natl Acad Sci U S A 105:10131-6. 2008
    ..Collectively, these findings support the conclusion that plant-produced idiotype vaccines are feasible to produce, safe to administer, and a viable option for idiotype-specific immune therapy in follicular lymphoma patients...
  10. ncbi Generating improved single-chain Fv molecules for tumor targeting
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunol Methods 231:249-60. 1999
    ..In this review, we describe a number of these methods and discuss some of the characteristics that may belong to an optimal antibody-based targeting vehicle...
  11. ncbi Improving the efficacy of antibody-based cancer therapies
    P Carter
    Immunex, Seattle, Washington 98101, USA
    Nat Rev Cancer 1:118-29. 2001
    ..Although antibodies have yet to achieve the ultimate goal of curing cancer, many innovative approaches stand poised to improve the efficacy of antibody-based therapies...
  12. ncbi Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer
    S E Monstad
    Department of Neurology, 200301028, Haukeland University Hospital, Jonas Liesvei 65, Bergen 5021, Norway
    J Clin Oncol 22:795-800. 2004
    ..These antibodies may reduce tumor growth in patients with the neurologic disease, but it is not clear whether they provide prognostic information in those without neurologic symptoms...
  13. ncbi Infectious complications associated with alemtuzumab use for lymphoproliferative disorders
    Stanley I Martin
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 43:16-24. 2006
    ..Alemtuzumab is an emerging therapy for refractory lymphoproliferative disorders. The associated long-term risks of infection remain poorly defined...
  14. pmc Human neoplasms elicit multiple specific immune responses in the autologous host
    U Sahin
    Medizinische Klinik und Poliklinik, Innere Medizin I, University of Saarland Medical School, Homburg, Germany
    Proc Natl Acad Sci U S A 92:11810-3. 1995
    ....
  15. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  16. ncbi High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
    M L Disis
    Department of Medicine, University of Washington, Seattle 98195 6527, USA
    J Clin Oncol 15:3363-7. 1997
    ....
  17. ncbi A human protein atlas for normal and cancer tissues based on antibody proteomics
    Mathias Uhlen
    Department of Biotechnology, AlbaNova University Center, Royal Institute of Technology KTH, SE 106 91 Stockholm, Sweden
    Mol Cell Proteomics 4:1920-32. 2005
    ..Our results suggest it should be possible to extend this analysis to the majority of all human proteins thus providing a valuable tool for medical and biological research...
  18. ncbi Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens
    Jian Ying Zhang
    W M Keck Autoimmune Disease Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Cancer Epidemiol Biomarkers Prev 12:136-43. 2003
    ....
  19. ncbi Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers
    Jeremy C Miller
    The Van Andel Research Institute, Grand Rapids, MI 49503, USA
    Proteomics 3:56-63. 2003
    ..These developments enable the immediate use of high-density antibody and protein microarrays in biomarker discovery studies...
  20. ncbi Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity
    Holger Nuckel
    Department of Hematology, Medical School, University of Duisburg Essen, Germany
    Eur J Pharmacol 514:217-24. 2005
    ..Alemtuzumab significantly enhances apoptosis in chronic lymphocytic leukemia cells in vitro, especially in combination with a cross-linking anti-Fc-antibody, this effect being mediated by a caspase-dependent pathway...
  21. ncbi The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy
    Alasdair J Coles
    Department of Clinical Neurosciences, Box 165, Addenbrooke s Hospital, Cambridge CB2 2QQ, UK
    J Neurol 253:98-108. 2006
    ..These concepts are currently being tested in a controlled trial comparing Campath-1H and IFN-beta in the treatment of drug-naïve patients with early, active RR MS...
  22. ncbi Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
    Andrea G S Buggins
    Department of Haematological Medicine, Guy s, King s and Thomas School of Medicine, Denmark Hill, London, England
    Blood 100:1715-20. 2002
    ....
  23. ncbi CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath
    Rowena D Bainton
    Blood 100:3843-4. 2002
  24. ncbi Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results
    Dixon B Kaufman
    Department of Surgery, Division of Transplantation, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Am J Transplant 5:2539-48. 2005
    ..Alemtuzumab induction therapy was similar in efficacy to basiliximab in a prednisone-free maintenance immunosuppressive protocol for an ethnically diverse population of kidney transplant recipients...
  25. ncbi CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H
    D D Bloom
    University of Wisconsin Madison, Department of Surgery, Division of Solid Organ Transplantation, Madison, WI, USA
    Am J Transplant 8:793-802. 2008
    ..Together, these data suggest that Campath-1H promotes an increase in peripheral Tregs and may act as an intrinsic generator of Tregs in vivo...
  26. ncbi Numerical selection of optimal tumor imaging agents with application to engineered antibodies
    L E Williams
    Division of Radiology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
    Cancer Biother Radiopharm 16:25-35. 2001
    ..The diabody had the largest impulse response function, but renal uptake may limit its present usefulness...
  27. ncbi CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein
    Ozlem Tureci
    III Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany
    J Immunol Methods 289:191-9. 2004
    ..CrELISA is robust and provides a versatile high throughput procedure for the rapid evaluation of multiple antigens in large-scale serology...
  28. ncbi Serological immunoreactivity against colon cancer proteome varies upon disease progression
    Lucia De Monte
    Proteome Biochemistry, Tumor Immunology, Mass Spectrometry, Pathology, Surgery, Experimental Immunology, Cancer Immunotherapy and Gene Therapy Program, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy
    J Proteome Res 7:504-14. 2008
    ..The expression of these proteins was either confined or increased in tumor as compared to normal mucosa...
  29. ncbi Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33
    G Ritter
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 61:6851-9. 2001
    ..By using this new method, we were able to distinguish these two types of HAHAs in patients while on antibody treatment, allowing patients to be removed from study prior to the onset of severe infusion-related adverse events...
  30. pmc Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin
    Martin S Zand
    Division of Nephrology, University of Rochester Medical Center, 601 Elmwood Ave, Box 675, Rochester, NY 14642, USA
    Blood 107:2895-903. 2006
    ..We conclude that rATG is an effective agent for in vitro induction of apoptosis in multiple myeloma, and that exploratory clinical trials may be warranted...
  31. ncbi Empowering targeted therapy: lessons from rituximab
    Adam J Olszewski
    Division of Hematology and Oncology, St Luke s Roosevelt Hospital and Beth Israel Medical Center, New York, NY 10019, USA
    Sci STKE 2004:pe30. 2004
    ..Lessons learned from the research on rituximab may be applied to the rational development of antibody-based therapies against other forms of cancer...
  32. ncbi Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia
    J D Isaacs
    University of Leeds, UK
    Arthritis Rheum 44:1998-2008. 2001
    ..These data are also relevant to patients receiving lymphocytotoxic mAb therapy for other indications, and to patients receiving other lymphodepleting therapies such as autologous stem cell transplantation...
  33. ncbi Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
    David M Goldenberg
    Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    J Clin Oncol 24:823-34. 2006
    ....
  34. ncbi Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity
    Raphael Clynes
    Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Hematol Oncol Clin North Am 20:585-612. 2006
    ..Thus, engineered Fc domains with favorable affinities for specific FcR types may prove to be clinically superior...
  35. ncbi MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue
    M V Croce
    Centre of Basic and Applied Immunological Research CINIBA, Faculty of Medical Sciences, UNLP, La Plata, Argentina
    Histol Histopathol 21:849-55. 2006
    ..The immunohistochemical detection (IHC) of MUC1-CT employing a polyclonal antibody (CT33) in relation to CT2 monoclonal antibody (MAb) was analyzed. Western blot (WB) was used to determine the molecular mass of CT...
  36. ncbi Detection of pancreatic cancer using antibody microarray-based serum protein profiling
    Johan Ingvarsson
    Department of Immunotechnology, Lund University, Lund, Sweden
    Proteomics 8:2211-9. 2008
    ..Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures...
  37. ncbi Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A
    Maria Liljefors
    Department of Oncology Radiumhemmet, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Int J Cancer 105:717-23. 2003
    ..These results should be considered when designing antibody-based therapeutic protocols...
  38. pmc Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies
    Y T Chen
    Ludwig Institute for Cancer Research, New York Unit, NY
    Proc Natl Acad Sci U S A 91:1004-8. 1994
    ..Transfection of the MAGE-1 gene into a MAGE-1 mRNA-negative melanoma cell line resulted in the expression of the 46-kDa protein, confirming the identity of this protein as the MAGE-1 gene product...
  39. ncbi Interleukin 21 enhances antibody-mediated tumor rejection
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Cancer Res 68:3019-25. 2008
    ..These data further support the use of IL-21 in adjuvant settings where strong T cell-mediated immune responses to tumors can be generated...
  40. ncbi A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation
    Andreas Reiff
    Division of Rheumatology, Department of Pediatrics, Keck School of Medicine, University of Southern California, Childrens Hospital, Los Angeles 90027, USA
    Hematology 10:79-93. 2005
    ....
  41. ncbi Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity
    Vivian Goodell
    Tumor Vaccine Group, Center for Translational Medicine in Women s Health, University of Washington, Seattle, WA 98195 8050, United States
    J Immunol Methods 299:129-38. 2005
    ..Cell-based ELISA can be developed to be Clinical Laboratory Improvement Act (CLIA)-compliant and the flexibility of the approach will allow adaptation of the assay to multiple tumor antigen systems...
  42. ncbi Calcineurin inhibitor- and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation
    Rainer W G Gruessner
    Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
    Transplantation 79:1184-9. 2005
    ..The authors present a novel strategy for posttransplant immunosuppression that combines a depleting antibody with an antimetabolite, avoiding calcineurin inhibitors and steroids...
  43. ncbi Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients
    Jim Xiao
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Cancer Biother Radiopharm 20:16-26. 2005
    ..This study examined the pharmacokinetics and tissue localization of a humanized domain-deleted CC49 antibody (HuCC49DeltaC(H)2 MAb) in humans...
  44. ncbi Campath-1H in renal transplantation: The University of Wisconsin experience
    Stuart J Knechtle
    Department of Surgery, University of Winsconsin Medical School, Madison 53792 7375, USA
    Surgery 136:754-60. 2004
    ....
  45. ncbi Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay
    Iman Jilani
    Department of Hematopathology, Nichols Institute, Quest Diagnostics, 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, USA
    Leuk Res 28:1255-62. 2004
    ..This validated assay should help optimize the dosing and scheduling of alemtuzumab therapy. The underlying principles are also applicable to the measurement of other humanized antibodies using an appropriate anti-Ig...
  46. ncbi Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein
    Oliver Schmetzer
    Molecular Immunotherapy, Max Delbrück Centrum for Molecular Medicine, Berlin, Germany
    J Immunol 174:942-52. 2005
    ..Our study shows that EpCAM only rarely induces autoantibodies against native protein and emphasizes the importance of using extremely purified Ag preparations when evaluating Abs against tumor-associated Ags...
  47. ncbi Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49
    Uwe A Wittel
    Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Biochem Biophys Res Commun 329:168-76. 2005
    ..In animal studies, the radiolabeled sc(Fv)(2)-AngII construct exhibited similar uptake and a more homogeneous distribution within the tumor as compared to sc(Fv)(2)...
  48. ncbi Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion
    Jonathan P Pearl
    Transplantation Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Am J Transplant 5:465-74. 2005
    ..These data demonstrate that therapeutic depletion begets a limited population of functional memory-like T cells that are easily suppressed with certain immunosuppressants, but cannot be considered uniquely pro-tolerant...
  49. pmc Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein
    Paul J Yazaki
    Division of Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope, Duarte, CA 91010, USA
    Nucl Med Biol 35:151-8. 2008
    ..The radiometal-labeled version, which shows lower normal tissue accumulation than these recombinant antibodies, provides a promising and novel platform for antibody-based imaging agents...
  50. ncbi The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation
    Joseph F Magliocca
    Department of Surgery, Division of Organ Transplantation, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792 7375, USA
    Transpl Int 19:705-14. 2006
    ..We herein review some of the lessons learned from clinical experience to date in solid organ transplantation using alemtuzumab as an immunosuppressant...
  51. ncbi Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients
    Lanyan Fang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, 232 Parks Hall, 500 West 12th Avenue, Columbus, OH 43210, USA
    J Clin Pharmacol 47:227-37. 2007
    ..Clinical trial designs with at least 3 measurements of antibody disposition were found to be better than an empirical direct observation method for the optimal prediction of surgery time...
  52. ncbi Cancer immunomics using autoantibody signatures for biomarker discovery
    Michel Caron
    Protein Biochemistry and Proteomics Laboratory, UMR CNRS 7033 BioMoCeTi, Unité de Formation et de Recherche Santé Médecine Biologie Humaine, Paris 13 University, 93017 Bobigny Cedex, France
    Mol Cell Proteomics 6:1115-22. 2007
    ..Lastly the most important difficulty of any proteomically identified autoantibody signature is validation in patient cohorts or clinical samples...
  53. ncbi A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application
    M Montagna
    Clinical Pharmacokinetics Unit, IRCCS Fondazione Policlinico S Matteo, Pavia, Italy
    Int J Immunopathol Pharmacol 20:363-71. 2007
    ..This ELISA assay could be easily used to determine human serum levels of Alemtuzumab pre- and post-treatment to optimize dosing and scheduling and to study the relationship between dose and clinical response...
  54. ncbi Alemtuzumab (Campath-1H): a systematic review in organ transplantation
    Peter J Morris
    Centre for Evidence in Transplantation, Royal College of Surgeons of England and London School of Hygiene and Tropical Medicine, University of London, UK
    Transplantation 81:1361-7. 2006
    ..Alemtuzumab is an attractive agent for induction in organ transplantation, but there is a need for more and larger randomized trials with long-term follow-up before its true role can be established, particularly with respect to safety...
  55. ncbi Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients
    Alfred Zippelius
    Klinik und Poliklinik für Onkologie, Departement fur Innere Medizin, Universitatsspital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Cancer Immunol Immunother 56:249-58. 2007
    ..Implications for the understanding of spontaneous humoral immune responses are discussed...
  56. ncbi Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu
    Huma Mohsin
    Department of Chemistry, University of Missouri Columbia, Columbia, Missouri 65211, USA
    Bioconjug Chem 17:485-92. 2006
    ..When labeled with 149Pm, 166Ho, and 177Lu, MeO-DOTA-CC49 has potential for RIT of colorectal cancer and other carcinomas...
  57. ncbi Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results
    D B Kaufman
    Department of Surgery, Division of Transplantation, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Am J Transplant 6:331-9. 2006
    ..Alemtuzumab induction followed by steroid-free maintenance therapy with a tacrolimus/sirolimus-based immunosuppression regimen provided an effective, safe and cost-conscious approach to SPK transplantation...
  58. pmc Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia
    Phillip Scheinberg
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Blood 109:3219-24. 2007
    ....
  59. ncbi Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1
    Yoshiya Ohno
    Cell Biology Laboratory, Department of Pharmaceutical Sciences, School of Pharmacy, Kinki University, 4 1 Kowakae 3 chome, Higashiosaka shi, Osaka 577 8502, Japan
    Cancer Sci 99:1000-7. 2008
    ..Comparative immunohistochemical analyses of normal human tissues with anti-CD98 hc and anti-LAT1 revealed LAT1 to be an excellent molecular target for antibody therapy, possibly even superior to CD98 hc...
  60. ncbi The use of Campath-1H as induction therapy in renal transplantation: preliminary results
    Gaetano Ciancio
    Department of Surgery, Division of Transplantation, University of Miami School of Medicine, Miami, FL 33101, USA
    Transplantation 78:426-33. 2004
    ....
  61. ncbi Optimization of in vivo tumor targeting in SCID mice with divalent forms of 741F8 anti-c-erbB-2 single-chain Fv: effects of dose escalation and repeated i.v. administration
    G P Adams
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Immunol Immunother 40:299-306. 1995
    ..06 microgram/ml, at the 48-h point. These results suggest that multiple high-dose administrations of radiolabeled 741F8 (sFv')2 may lead to the selective tumor localization of therapeutic radiation doses...
  62. ncbi Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells
    Hanno Ehlken
    German Cancer Research Center DKFZ, Skin Cancer Unit D070, Heidelberg, Germany
    Int J Cancer 108:307-13. 2004
    ..We conclude that a strong humoral response against tumor-associated antigens is inducible by tumor cells and that this response is very individual...
  63. ncbi Methods and applications of antibody microarrays in cancer research
    Brian B Haab
    Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA
    Proteomics 3:2116-22. 2003
    ..These demonstrations clearly show the utility of antibody microarrays for cancer research and signal the imminent expansion of this platform to many areas of biological research...
  64. ncbi Proteomic profiling of the cancer microenvironment by antibody arrays
    V Knezevic
    Cancer Genome Anatomy Project, National Cancer Institute, NIH, Bethesda, MD, USA
    Proteomics 1:1271-8. 2001
    ....
  65. ncbi Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    G Hale
    Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
    Bone Marrow Transplant 30:797-804. 2002
    ....
  66. ncbi Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H)
    Xiuqing Ru
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Br J Haematol 123:278-81. 2003
    ..Alemtuzumab appears to be an effective and well-tolerated therapy for pure red blood cell aplasia associated with lymphoproliferative disorders...
  67. ncbi Immunoguided lymph node dissection in colorectal cancer: a new challenge?
    S Schneebaum
    Radioguided Surgery Unit, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv Sourasky Medical Center, Israel
    World J Surg 25:1495-8; discussion 1499. 2001
    ..Using this guideline, additional information acquired by RIGS can help the surgeon in making an informed decision during surgery and in planning postoperative therapy...
  68. ncbi Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy
    L Sanz
    Department of Immunology, Hospital Universitario Clinica Puerta de Hierro, Madrid, Spain
    Cancer Immunol Immunother 50:557-65. 2001
    ..and show strong immunohistochemical reactivity with basement membranes in human and murine tissue sections. Their properties make them ideal candidates for in vivo applications...
  69. ncbi Pharmacokinetics of CAMPATH-1H: assay development and validation
    Peppy Rebello
    Sir William Dunn School of Pathology, University of Oxford, South Parks Road, OX1 3RE, Oxford, UK
    J Immunol Methods 260:285-302. 2002
    ..This validated assay is suitable for the measurement of CAMPATH-1H levels in clinical trials and the same principles may be applied to any other cell-binding monoclonal antibody...
  70. ncbi Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients
    D Usener
    Skin Cancer Unit, D070, German Cancer Research Centre, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
    Br J Dermatol 149:282-8. 2003
    ..Cancer-testis antigens exemplify a growing number of tumour antigens which are expressed in a variety of malignancies, but not in normal tissues other than germ cells, primarily those of the testis...
  71. ncbi Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H)
    Allan D Kirk
    Transplantation and Autoimmunity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Transplantation 76:120-9. 2003
    ..We therefore performed a study to determine if pretransplant T-cell depletion with alemtuzumab would induce tolerance in human renal allografts and to evaluate the nature of the alloimmune response in the setting of T-cell depletion...
  72. ncbi Ligand-targeted liposomal anticancer drugs
    P Sapra
    Department of Pharmacology, University of Alberta, Edmonton AB, Canada, T6G 2H7
    Prog Lipid Res 42:439-62. 2003
    ..The time is rapidly approaching where we will see translation of anticancer drugs entrapped in LTLs to the clinic...
  73. ncbi Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab
    Kirsten E Herbert
    Blood 101:1654. 2003
  74. ncbi Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma
    Richard D Unwin
    Cancer Research UK Clinical Cancer Centre, St James s University Hospital, Leeds, UK
    Proteomics 3:45-55. 2003
    ....
  75. ncbi Polyclonal anti-colorectal cancer Fab phage display library selected in one round using density gradient centrifugation to separate antigen-bound and free phage
    Brent R Williams
    Department of Pathology and Laboratory Medicine, the Hubert H Humphrey Cancer Research Center, Boston University School of Medicine, Room K707, 715 Albany Street, Boston, MA 02118, USA
    Immunol Lett 81:141-8. 2002
    ..It is also applicable for selection of peptide or other phage display libraries on any insoluble ligand...
  76. ncbi Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    Michael J Keating
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 99:3554-61. 2002
    ..Alemtuzumab induced significant responses in these patients with clinical benefit in the majority and with acceptable toxicity in a high-risk group...
  77. ncbi Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins
    A Sreekumar
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 61:7585-93. 2001
    ..Taken together, our work suggests that protein/antibody microarrays will facilitate high-throughput proteomic studies of human cancer and carcinogenesis...
  78. ncbi Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
    Geoff Hale
    Therapeutic Antibody Centre, Old Road, Headington, Oxford, OX3 7JT, United Kingdom
    Blood 104:948-55. 2004
    ..Subcutaneous alemtuzumab is more convenient and better tolerated but may be associated with some patients forming anti-alemtuzumab antibodies, particularly those patients who were previously untreated...
  79. ncbi Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice
    R M Tempero
    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha 68198, USA
    Int J Cancer 80:595-9. 1999
    ..Additional studies showed that polyclonal sera containing IgG1 Abs reactive with MUC1 TR were unable to provide protection against the growth of syngeneic tumors expressing MUC1 in the MUC1.Tg animal model...
  80. ncbi Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin
    S von Mensdorff-Pouilly
    Departments of Obstetrics and Gynecology, Clinical Chemistry, Pathology, and Surgery, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Clin Oncol 18:574-83. 2000
    ..The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease...
  81. ncbi High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H
    C E Dearden
    Royal Marsden NHS Trust, London, United Kingdom
    Blood 98:1721-6. 2001
    ..The conclusion is that CAMPATH-1H is an effective therapy in T-PLL, producing remissions in more than two thirds of patients. The use of stem cell transplantation to consolidate responses merits further study...
  82. ncbi A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates
    Richard Lo-Man
    Unité de Biologie des Régulations Immunitaires Institut National de la Santé et de la Recherche Médicale E352 Institut Pasteur, 25 28 Rue du Dr Roux, 75724 Paris, France
    Cancer Res 64:4987-94. 2004
    ....
  83. ncbi Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma
    Doreen M Agnese
    Divisions of Surgical Oncology, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, Ohio, USA
    Ann Surg Oncol 11:197-202. 2004
    ..This study was designed to assess the clearance, safety, and effectiveness of localization of a complimentarity determining region (CDR)-grafted humanized domain-deleted antitumor CC49 antibody (HuCC49DeltaCH2)...
  84. ncbi Mechanism of action and resistance to monoclonal antibody therapy
    Neus Villamor
    Unitat d Hematopatologia, Hospital Clinic, Barcelona, Spain
    Semin Oncol 30:424-33. 2003
    ..We review the current understanding of the mechanism of action of and resistance to these MoAbs...
  85. ncbi Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies
    Kumi Oshima
    Department of Hematology, Cell Therapy and Transplantation Medicine, University of Tokyo Graduate School of Medicine and Hospital, Tokyo, Japan
    Am J Hematol 81:875-9. 2006
    ....
  86. ncbi The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies
    M J Dyer
    Institute of Cancer Research Royal Marsden Hospital, Sutton, Surrey, UK
    Semin Oncol 26:52-7. 1999
    ..Further experiments to enhance the activity of CD52 antibodies in sites refractory to antibody alone are currently being undertaken...
  87. ncbi Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    Jeanette Lundin
    Department of Hematology, Karolinska Hospital, and Huddinge University Hospital, Stockholm, Sweden
    Blood 100:768-73. 2002
    ..Prolonged treatment is important for maximal bone marrow response. Subcutaneous administration induced very few "first-dose" flulike symptoms and may reduce health care costs in comparison with the intravenous infusions...
  88. ncbi Bi-specific antibody therapy for the treatment of cancer
    S Withoff
    Groningen University Institute for Drug Exploration, University Hospital Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
    Curr Opin Mol Ther 3:53-62. 2001
    ..The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy...
  89. ncbi Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
    Mohammad Reza Rezvany
    Immune and Gene Therapy Laboratory, Department of Oncology and Pathology, Cancer Centre Karolinska CCK, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 135:475-85. 2006
    ..These results indicate that perturbations in the T-cell alterations following alemtuzumab are complex and include not only changes in CD4/CD8 T-cell numbers but also a highly restricted T-cell repertoire especially in CD4 T cells...
  90. ncbi Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
    Susan M O'Brien
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 7:125-30. 2006
    ....
  91. ncbi Alemtuzumab in CLL and other lymphoid neoplasms
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer Invest 24:718-25. 2006
    ..Effective antibiotic prophylaxis can limit the incidence of infections, which are the major side effect associated with the profound lymphopenia occurring as a result of treatment with this agent...
  92. ncbi Alemtuzumab in the treatment of chronic lymphocytic lymphoma
    Kevin Boyd
    The Royal Marsden Hospital and Institute of Cancer Research, London, UK
    Expert Rev Anticancer Ther 8:525-33. 2008
    ..It seems to be particularly useful in patients with CLL who have deletion of the TP53 tumor suppressor gene, a subset of disease that responds poorly to other currently available chemotherapeutics...
  93. ncbi Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia
    L Alinari
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Oncogene 26:3644-53. 2007
    ..Additional studies detailing the mechanism of action of alemtuzumab as well as new strategies for prevention of opportunistic infections will aid in the future therapeutic development of this agent...
  94. ncbi Advances in the use of alemtuzumab in CLL
    Stephan Stilgenbauer
    Department of Haematology, Oncology, Rheumatology, and Infectious Diseases, University of Ulm, 89069 Ulm, Germany
    Clin Adv Hematol Oncol 6:23-4. 2008
  95. ncbi Alemtuzumab in Sézary syndrome: efficient but not innocent
    Umit Barbaros Ure
    Istanbul University Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul University Cerrahpasa Medical Faculty, 34300, Istanbul, Turkey
    Eur J Dermatol 17:525-9. 2007
    ..We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection...
  96. ncbi Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model
    Ning Li
    Department of Immunology, Cancer Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    Immunol Lett 113:90-8. 2007
    ..These findings demonstrate that this combinatorial treatment can elicit a potent anti-tumor immune response and suggest potential of this approach for treatment of prostate cancer...
  97. ncbi CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymp
    Raymond I Cruz
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 48:2424-36. 2007
    ..Our current data provides a basis for further evaluation of alemtuzumab-based clinical trials for patients with rituximab-resistant NHL...
  98. ncbi [Monoclonal antibody therapy: a literature review]
    Carolina Beltrame Del Debbio
    Escola de Enfermagem, Universidade de Sao Paulo
    Rev Gaucha Enferm 28:133-42. 2007
    ..0% cause digestive side effects, and 87.5% affect the hematopoietic system. In order to guarantee MA's therapeutic efficacy and safety, professionals must fully understand their pharmacological characteristics...
  99. ncbi In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia
    Mario De Decker
    Department of Radiopharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
    Nucl Med Biol 35:599-604. 2008
    ..Therefore, (188)Re-alemtuzumab would be an ideal candidate for radioimmunotherapy of chronic lymphocytic leukemia...
  100. ncbi A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 14:569-78. 2008
    ..We describe generation and utilization of cell lines that stably express CD52 both in vitro and in vivo...
  101. ncbi Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia
    Susanne Auffermann-Gretzinger
    Medizinische Klinik und Poliklinik I Universitätsklinikum Dresden, Dresden, Germany
    Transplantation 83:1268-72. 2007
    ....

Research Grants71

  1. Thymocyte tuning after selection: mechanisms to avoid autoreactivity
    Terri M Laufer; Fiscal Year: 2010
    ..These experiments will define the mechanisms which regulate a critical thymic pathway that the immune system utilizes to avoid autoreactivity. ..
  2. Campath-1H & Calcineurin-Inhibitors in Renal Transplant
    Stuart Knechtle; Fiscal Year: 2007
    ..abstract_text> ..
  3. The regulation of tumor immunity by NKT cells
    Mark Smyth; Fiscal Year: 2007
    ..This proposal focuses clearly on a pivotal immune control mechanism that will influence many current and future immunotherapies. ..
  4. TRANSPLANTATION TOLERANCE USING IMMUNOTOXIN
    Stuart Knechtle; Fiscal Year: 2001
    ..The goal of this proposal would be to develop adequate preclinical data to permit phase I and II clinical trials in organ transplant recipients. ..
  5. CMMI Human Subject Research Enhancement Program
    David Goldenberg; Fiscal Year: 2002
    ..3.) Provide travel expenses and educational materials for IRB members, investigators, and Regulatory Affairs Office personnel to attend meetings for educational enhancement. ..
  6. Clofarabine: Cytarabine Activation for Leukemia Response
    Stefan Faderl; Fiscal Year: 2004
    ..abstract_text> ..
  7. 9/10TH Conf./Cancer Therapy/Antibody/Immunoconjugates
    David Goldenberg; Fiscal Year: 2004
    ..The conference chairman, Dr. Goldenberg, has secured two outstanding scientists as co-chairmen, Drs. Ralph Reisfeld (Scripps) and Edward Sausville (NCI). ..
  8. Pretargeting mouse tumor with anti-PSMA antibody-MORF
    Guozheng Liu; Fiscal Year: 2005
    ..Based on our experiences in this pretargeting strategy, we are confident that these investigations on the pretargeting imaging of prostate cancer models with MORFs will be successful. ..
  9. 11th & 12th Conference on Cancer Therapy with Antibodies and Immunoconjugates
    David Goldenberg; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  10. Renal Transplantation Using Campath1H/Rapamycin
    Stuart Knechtle; Fiscal Year: 2003
    ..This data will be correlated with histopathology of protocol biopsies. ..
  11. Radioimmunotherapy for Prostate Cancer
    Michael Morris; Fiscal Year: 2007
    ..The acquisition of these skills combined with the completion of the research plan will allow the candidate to pursue such research independently. ..
  12. Longitudinal Cancer-Specific Serum Protein Signatures
    Brian Haab; Fiscal Year: 2006
    ..The successful demonstration of the approach to prostate cancer diagnostics will signal its potential usefulness for all types of biomarker studies. [unreadable] [unreadable] [unreadable]..
  13. U. of Wisconsin Transplant Research Training Program
    Stuart Knechtle; Fiscal Year: 2006
    ....
  14. ANTIBODIES AND ANTIGENS IN HEPATOCELLULAR CARCINOMA
    ENG TAN; Fiscal Year: 2005
    ..Other studies are to determine the target genes(s) of SG2NA and potential protein binding partners. Elucidation of the properties and function of these proteins might contribute to understanding co-activating factors in carcinogenesis. ..
  15. CXCR3 Chemokine Receptor in Non-Human Primate Allograft
    Stuart Knechtle; Fiscal Year: 2006
    ..We plan to take advantage of the combined experience of the Hancock and Knechtle labs to address the research questions posed herein. ..
  16. Defining Secreted Glycan Alterations in Pancreatic Cancer
    Brian Haab; Fiscal Year: 2006
    ..This research could lead to significantly improved blood tests for the detection of cancer, as well as a powerful, generally- applicable platform for studying carbohydrate alterations on multiple proteins. ..
  17. Tumor specific cell sruface epitope- molecular evolution
    Bin Liu; Fiscal Year: 2005
    ..The resulting antibodies will have a very high likelihood of recognizing clinically relevant tumor antigens. ..
  18. Planning Grant for Institutional Clinical and Translational Science Award
    MARY DISIS; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  19. Protein targets of ovarian and oocyte autoantibodies
    Judith Luborsky; Fiscal Year: 2007
    ..It will also contribute to a better understanding of an autoimmune disease that affects women's health. ..
  20. FcR Enhanced Ag Presentation--Induction Tumor Immunity
    Raphael Clynes; Fiscal Year: 2006
    ..3) Determine whether FcgammaR uptake enhances class I antigen presentation in human systems and specifically whether antibody-mediated T cell priming occurs in Trastuzumab-treated patients. ..
  21. Phase I Trial of a HER2 ICD Plasmid-Based DNA Vaccine
    MARY DISIS; Fiscal Year: 2007
    ..The long-term goal will be to use this study as a platform to develop multi-antigen plasmid based vaccines for the prevention of common solid tumors. ..
  22. Isolation of human tumor cells in dormant cancer
    Jonathan Uhr; Fiscal Year: 2007
    ..abstract_text> ..
  23. Pathogenic Role of Islet Cell Abs in Autoimmune Diabetes
    Raphael A Clynes; Fiscal Year: 2010
    ..We propose in Aim 3 to extend this work to test relevance to the antibody-mediated cross-presentation of insulin, an antigen of singular importance to diabetes. ..
  24. Multi-Antigen Vaccines for Breast Cancer
    MARY DISIS; Fiscal Year: 2007
    ..abstract_text> ..
  25. A Novel Computational Framework for Individualized Clinical Decision-Making
    Nancy Lan Guo; Fiscal Year: 2010
    ..This study will advance the computational modeling of human genome data in disease for clinical decision-making. ..
  26. Retargeted Oncolytic Measles Viruses Displaying Single-Chain Antibodies
    Kah Whye Peng; Fiscal Year: 2010
    ..3) To determine the relationship between affinity of displayed scFv and virus entry or cell fusion of retargeted MVs. ..
  27. Ligation of CR3 by Glucan and iC3b Links Innate and Adaptive Anti-tumor Immunity
    Jun Yan; Fiscal Year: 2009
    ..The enhancing effect of beta-glucan on anti-MUd T and B cell responses will be determined. Beta-glucan mediated immunotherapy demonstrates promising results in the therapeutic setting and is potentially remedial for cancer patients. ..
  28. Cytoprotective Effect of CO in Lung Ischemia/Reperfusion
    Kenneth McCurry; Fiscal Year: 2008
    ..abstract_text> ..
  29. Photothermal Imaging of Live Cells
    Vladimir Zharov; Fiscal Year: 2008
    ..The technical realization of PTI is relatively simple, requiring the combination of conventional optical phase-contrast microscopy and the already routinely used nanosecond laser. ..
  30. The influence of ischemic microenvironment and stem cell differentiation
    Randall Lee; Fiscal Year: 2008
    ..unreadable] Specific aim 2: To test the hypothesis that the microenvironment influences SC differentiation, angiogenesis and LV remodeling. [unreadable] [unreadable] [unreadable]..
  31. Lentivirus Gene Therapy for Farber Disease in NHPs
    Jeffrey Medin; Fiscal Year: 2007
    ..This proposed study would thus be the first to fully test LV-mediatedcorrection for an LSD in a more clinically relevant model; that of NHPs. ..
  32. Blood Test Detects Change from HER2- to + in Breast Cancer
    Jonathan Uhr; Fiscal Year: 2007
    ..This would ensure that patients who acquire treatable changes in their tumor will receive optimal targeted therapy. ..
  33. 4th International Conference on Oncolytic Viruses as Cancer Therapeutics
    Kah Whye Peng; Fiscal Year: 2007
    ..This provides an important training ground for tomorrow's scientists. [unreadable] [unreadable] [unreadable] [unreadable]..
  34. Antibody Microarrays for Cancer Diagnostics
    ULRIK NIELSEN; Fiscal Year: 2007
    ..The development of high quality antibody reagents for use in the construction of micro arrays will have broad implications in making diagnostic and research tools. [unreadable] [unreadable]..
  35. Rational Design of Therapeutic Vaccines for CEA+ Tumors
    SUNIL CHATTERJEE; Fiscal Year: 2007
    ..The results obtained from these studies will help design improved therapeutic vaccines for the treatment of CEA+ tumors and can be incorporated readily into our ongoing clinical programs. ..
  36. Phase II trial of 17-AAG in melanoma patients
    Paul Chapman; Fiscal Year: 2007
    ..post-treatment specimens, clinically responding tumors vs. non-responding tumors, and mutant BRAF vs. wild-type BRAF tumors. [unreadable] [unreadable] [unreadable]..
  37. Anti-GD3 NKT cells as effector cells against melanoma
    Paul Chapman; Fiscal Year: 2006
    ..This will provide initial support for an immunotherapeutic approach based on antigen-specific NKT cells. [unreadable] [unreadable]..
  38. Intracerebral Infusion of Radiolabeled Specific Antibody
    John Sampson; Fiscal Year: 2006
    ..abstract_text> ..
  39. PATHOBIOCHEMISTRY OF ACUTE PROMYELOCYTIC LEUKEMIA
    Edward Yeh; Fiscal Year: 2004
    ..These studies should provide novel insights into the mechanism and function of sentrinization and increase our understanding of the pathogenesis of acute promyelocytic leukemia. ..
  40. Integrated optical imaging rat of mesentery
    Vladimir Zharov; Fiscal Year: 2004
    ..The technical realization of this new imaging system is relatively simple, combining transmission microscopy and laser technique already routinely in use. ..
  41. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    John Sampson; Fiscal Year: 2004
    ....
  42. HER2 VACCINATION FOR THE TREATMENT OF CANCER
    MARY DISIS; Fiscal Year: 2004
    ....
  43. Rational Optimization of Protein Solubility
    JOHN DESJARLAIS; Fiscal Year: 2003
    ..abstract_text> ..
  44. DENDRITIC CELL IMMUNOTHERAPY FOR LUNG AND COLON CANCER
    Lawrence Fong; Fiscal Year: 2003
    ..The proposed studies will provide the foundation for simplified yet more potent DC targeted cancer immunotherapy for the future. ..
  45. IMMUNIZATION AGAINST TUMOR CELL ANTIGENS
    Paul Chapman; Fiscal Year: 2003
    ..This close mentoring relationship reflects our current teaching paradigm. The grant award will provide the PI with more time to conduct the clinical trials and to mentor additional beginning clinical investigators. ..
  46. TRANSPLANT IMMUNOLOGY OF IL2 IFNY DOUBLE KNOCKOUT MICE
    Martin Zand; Fiscal Year: 2002
    ..In contrast, if the DKO mice are tolerant to islet allografts, we will determine the mechanism by adoptive transfer of tolerance inducing T lymphocyte subsets. ..
  47. VACCINES ELICITING CD8 CYTOTOXIC T CELL RESPONSES
    Herman Eisen; Fiscal Year: 2002
    ....
  48. EVALUATION OF CH2 DELETED HUCC49 FOR INTRAPERITONEAL RIT
    Donald Buchsbaum; Fiscal Year: 2001
    ..These studies would establish the rationale for human clinical RIT trials in patients with intraperitoneal cancer using HuCC49deltaCH2 and the optimum method of administration of IFN. ..
  49. EARLY DETECT/CHARACTERIZATION OF TUMOR CELLS IN BLOOD
    Jonathan Uhr; Fiscal Year: 2001
    ....
  50. NEW BCAS FOR RADIOIMMUNOTHERAPY WITH RADIOMETALS
    Donald Buchsbaum; Fiscal Year: 2001
    ..The experiments described in this application will provide answers to these questions. These studies would establish the rationale for human clinical RIT trials in patients with Jp. cancer using HuCC49ACH2. ..
  51. PHASE I TRIAL OF A PEPTIDE VACCINE AGAINST EGFRVIII
    Bruce Montgomery; Fiscal Year: 2005
    ..To characterize effects of human anti-EGFRvIII antibodies on EGFRvIII signaling. 4. To determine the level of EGFR specific T cell response after immunization with EGFRvIII peptide. ..
  52. Antibody fragment drug conjugates for cancer therapy
    Paul Carter; Fiscal Year: 2005
    ..Advances made with anti-CD30 antibody fragment drug conjugates are anticipated to be broadly applicable to other antibodies with therapeutic potential. ..
  53. Serum Citrulline in Rejection of Intestinal Transplants
    Andreas Tzakis; Fiscal Year: 2006
    ..Discovery of a serum marker of intestinal rejection will make its detection possible without invasive tests, cheaper even from a distance. It will improve the safety and outcomes of intestinal transplants. ..
  54. Bioluminescent Imaging of Pancreatic Islet Transplants
    Dixon Kaufman; Fiscal Year: 2005
    ..abstract_text> ..
  55. HER 2/Neu--A Target For Cancer Immunotherapy
    MALAYA CHATTERJEE; Fiscal Year: 2005
    ..This study will be a prelude to clinical trials for HER2/neu positive cancer patients with a single or combined anti-Id vaccine. ..
  56. Anti-GM1b IgM for Detection of Localized Prostate Cancer
    Mepur Ravindranath; Fiscal Year: 2005
    ....
  57. INVESTIGATION INTO THE FUNCTION OF FIG1
    Charles Chu; Fiscal Year: 2001
    ....
  58. Immunotoxin-Induced Vascular Leak Syndrome
    Ellen Vitetta; Fiscal Year: 2005
    ..3) whether there are correlations between PKs, changes in cytokines, toxicity, and response. Our data will be compared with those obtained in the past clinical trials with the second generation IT, RFB4-dgRTA. ..
  59. PHASE 1 STUDY OF SAFETY & IMMUNOGENICITY OF AN ALUM-FORMULATED RECOMBINANT RICIN
    Ellen Vitetta; Fiscal Year: 2009
    ..Doses of 1, 10 and 100 micrograms - each with 0.5 mg Alhydrogel, will be given at weeks 0, 6, and 26 and serum will be assessed for anti-vaccine and neutralizing titers. ..
  60. Investigation into human IL4I1
    Charles Chu; Fiscal Year: 2005
    ..abstract_text> ..
  61. MENTORING & ADVANCED RESEARCH TRAINING FOR WRHR SCHOLARS
    Jonathan Berek; Fiscal Year: 2008
    ..This cadre of Scholars will be among future leaders in women's reproductive health research in the United States. [unreadable] [unreadable] [unreadable]..
  62. The reversal of multidrug resistance by an anti-CD19 ab.
    Ellen Vitetta; Fiscal Year: 2006
    ..abstract_text> ..
  63. T cell diversity in the induction of autoimmunity
    Terri Laufer; Fiscal Year: 2006
    ..Understanding the requirements for T cell diversity and the interactions between "graft" T cells and host antigen presenting cells offers improved immunologic targets for preventing GVHD following bone marrow transplant. ..
  64. SIGNALING AND ANTITUMOR EFFECTS OF ANTIBODIES
    Ellen Vitetta; Fiscal Year: 2001
    ..These tumors will be used as targets for therapy. To this end, she has initiated collaborations at her institution and at two other institutions for the acquisition of fresh lymphomas. ..
  65. A Novel Recombinant Protein Vaccine Against Ricin Toxin
    Ellen Vitetta; Fiscal Year: 2006
    ..When these three aims are completed, the vaccine should be ready for acute toxicology studies in two species and scale-up for Phase 1 clinical trials in humans. [unreadable] [unreadable]..
  66. DC-CD4 interactions in Th2 differentiation
    Terri Laufer; Fiscal Year: 2006
    ..abstract_text> ..
  67. Tumor-reactive IgG in the diagnosis of ovarian cancer
    Douglas Taylor; Fiscal Year: 2005
    ..Ultimately, antigenic proteins, linked with histologic type and stage of disease, will be combined into the development of protein arrays to screen for circulating reactive IgG as an early diagnostic test. ..
  68. RADIOIMMUNOTHERAPY OF B CELL LYMPHOMA WITH ANTI CD74
    M Mattes; Fiscal Year: 2002
    ..This study may lead to the development of more effective radio-conjugates for the therapy of cancer and other diseases. Also, it will provide basic information about the toxic effects of intracellular (really lysosomal) radionuclides. ..
  69. MESOTHELIN ANTIGENS FOR DIAGNOSIS/THERAPY OF OVARIAN CA
    Ingegerd Hellstrom; Fiscal Year: 2003
    ..As part of this study, she shall investigate whether the soluble MR molecule (SMR) can act as an inhibitor of the immune response and, if so, whether the inhibition can be overcome. ..
  70. Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES
    John Byrd; Fiscal Year: 2006
    ..abstract_text> ..
  71. IMMUNOTOXIN-DEPLETION OF HIV-1+T CELLS
    Ellen Vitetta; Fiscal Year: 2003
    ..This is a preclinical study to evaluate a new therapeutic modality. Our results should determine the feasibility of a future clinical trial. ..